Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of CD133<+> endothelial precursor cells

A technology of endothelial precursor cells and uses, which can be used in medical preparations containing active ingredients, skin diseases, metabolic diseases, etc., and can solve problems such as large trauma, poor wound healing, and intolerable time

Inactive Publication Date: 2015-05-20
TENTH PEOPLES HOSPITAL OF TONGJI UNIV +1
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Medical treatment can only be used as an adjuvant treatment to slow down the deterioration of diabetic foot, while vascular transplantation and vascular reconstruction surgery in surgical treatment all face consequences such as poor postoperative wound healing and unsatisfactory recanalization of blood vessels, and most severe diabetic patients are elderly patients , also concurrent with multiple cardiovascular diseases, unable to tolerate long-term and traumatic vascular transplantation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of CD133&lt;+&gt; endothelial precursor cells
  • Use of CD133&lt;+&gt; endothelial precursor cells
  • Use of CD133&lt;+&gt; endothelial precursor cells

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0115] The selection and grouping of the clinical cases of embodiment 1

[0116] 1.1 Take 30 patients with diabetic foot, the inclusion criteria:

[0117] (1) History of diabetes > 10

[0118] (2) Age ≤ 75 years old

[0119] Lower extremity ischemia 2 ≤ Rutherford grade (Table 1) ≤ 4

[0120] (3) Ankle-brachial index (ABI)<0.7

[0121] (4) The anterior tibial, posterior tibial, and peroneal arteries at the distal end of the popliteal artery of the affected limb were identified by angiography (DSA), and one or two arteries were narrowed by more than 50%.

[0122] 1.2 The exclusion criteria are met when one of the following situations occurs:

[0123] (1) Hemoglobin <10mg / dl

[0124] (2) Creatinine clearance rate <30ml / min

[0125] (3) Have received stem cell therapy before

[0126] (4) Suffering from mental illness

[0127] (5) During the treatment follow-up period, the 2hr postprandial blood glucose monitoring exceeds 11.1mmol / L for 4 consecutive weeks

[0128] (6) Du...

Embodiment 2

[0139] Example 2 CD133 ＋ Acquisition of EPCs and combined treatment plan

[0140] 2.1. For all the subjects in Example 1, 100 ml of venous blood will be collected through the central vein and anticoagulated with heparin.

[0141] The blood of subjects in group A will be handed over to the GMP-certified East China Stem Cell Bank laboratory for CD133 testing within 24 hours according to general method 1. ＋ After the magnetic bead sorting of EPCs, endotoxin and other routine blood product safety tests are passed, aseptic packaging (50ml suspension, cell volume ≥ 2×10 7 ), stored and transported at a constant temperature of 4°C. The blood of subjects in group B will be used for laboratory research.

[0142] 2.2. Basic treatment of diabetes

[0143] Blood glucose control plan and related standardized routine treatment will be formulated by endocrinology specialist, and PTA / CD133 will be tested before blood collection ＋ After EPCs treatment, the 2hr postprandial blood glucose w...

Embodiment 3

[0159] Embodiment 3 follows up a case by regular visits to the patient in embodiment 2 result

[0160] Follow-up arrangements are shown in Table 2

[0161] Table 2

[0162]

[0163] The basic information of the patients is shown in Table 3: 14 cases, type II diabetes

[0164] table 3

[0165] age 55-83 years old

[0166] 6 male cases (1 case 2 times), 7 female cases Before the follow-up visit 2012.12.18-2013.06.30 average age 69.77±9.66 years old Lower Extremity Pain Relief 13 / 14 Lower extremity cold improved 13 / 14 ulcer healing 2 / 3 ABI improvement 12 / 14 limb salvage 14 / 14

[0167] For specific results, see Figure 5-Figure 7 :

[0168] in, Figure 5 It shows that the overall ABI index and blood flow velocity of the patients after the operation are better than before. Figure 6 a-c shows that the postoperative follow-up is compared with the preoperative, and the patient's red blood cell, le...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a use of CD133<+> endothelial precursor cells, and concretely relates to a use of the CD133<+> endothelial precursor cells in the preparation of medicinal compositions for treating diabetic foot. The specific endothelial precursor cells can substantially improve the symptoms of diabetic foot patients in a specific intra-arterial application mode, and even reverse serious diabetic foot patients in order to provide a new clinic application for the treatment of the diabetic foot. The CD133<+> endothelial precursor cells are autologous, are used in autograft, have no ethical defects, and are safe and feasible.

Description

technical field [0001] The present invention relates to the field of interventional therapy, in particular to CD133 ＋ Use of endothelial precursor cells in the diabetic foot. Background technique [0002] Diabetic foot refers to a lesion in which the foot or lower extremity tissues of diabetic patients are destroyed due to factors such as diabetic vascular disease and (or) neuropathy and infection. Serious diabetic complications that threaten diabetic patients have a serious impact and burden on patients, their families, and society. [0003] For now, the treatment of diabetic foot is mainly divided into internal medicine and surgical treatment. Among them, medical treatment includes control of hyperglycemia, intravenous injection of drugs to improve microcirculation and nerve function, application of effective antibiotics, and treatment combined with hyperbaric oxygen and traditional Chinese medicine; Surgical treatment, local treatment of wounds, endovascular interventio...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/14A61K35/28A61K47/42A61P3/10A61P17/00
Inventor 李茂全王学军陆晨晖曹传武徐霁充唐涛韩世龙章靖徐志国刘拥军贡波
Owner TENTH PEOPLES HOSPITAL OF TONGJI UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com